These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

888 related articles for article (PubMed ID: 32028068)

  • 21. Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy.
    Bochem J; Zelba H; Spreuer J; Amaral T; Wagner NB; Gaissler A; Pop OT; Thiel K; Yurttas C; Soffel D; Forchhammer S; Sinnberg T; Niessner H; Meier F; Terheyden P; Königsrainer A; Garbe C; Flatz L; Pawelec G; Eigentler TK; Löffler MW; Weide B; Wistuba-Hamprecht K
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34933966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gene expression and immune infiltration in melanoma patients with different mutation burden.
    Wang L; Chen F; Liu R; Shi L; Zhao G; Yan Z
    BMC Cancer; 2021 Apr; 21(1):379. PubMed ID: 33836680
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PMEL as a Prognostic Biomarker and Negatively Associated With Immune Infiltration in Skin Cutaneous Melanoma (SKCM).
    Zhang S; Chen K; Liu H; Jing C; Zhang X; Qu C; Yu S
    J Immunother; 2021 Jul-Aug 01; 44(6):214-223. PubMed ID: 34028390
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma.
    Huang FX; Wu JW; Cheng XQ; Wang JH; Wen XZ; Li JJ; Zhang Q; Jiang H; Ding QY; Zhu XF; Zhang XS; Ding Y; Li DD
    Front Immunol; 2022; 13():902167. PubMed ID: 36003385
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development and Validation of a CD8+ T Cell Infiltration-Related Signature for Melanoma Patients.
    Yuan Y; Zhu Z; Lan Y; Duan S; Zhu Z; Zhang X; Li G; Qu H; Feng Y; Cai H; Song Z
    Front Immunol; 2021; 12():659444. PubMed ID: 34040608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor Immune Microenvironment Characterization Identifies Prognosis and Immunotherapy-Related Gene Signatures in Melanoma.
    Liu D; Yang X; Wu X
    Front Immunol; 2021; 12():663495. PubMed ID: 34025664
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab).
    Fietz S; Zarbl R; Niebel D; Posch C; Brossart P; Gielen GH; Strieth S; Pietsch T; Kristiansen G; Bootz F; Landsberg J; Dietrich D
    Cancer Immunol Immunother; 2021 Jun; 70(6):1781-1788. PubMed ID: 33196890
    [TBL] [Abstract][Full Text] [Related]  

  • 28. LAYN Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Gastric and Colon Cancers.
    Pan JH; Zhou H; Cooper L; Huang JL; Zhu SB; Zhao XX; Ding H; Pan YL; Rong L
    Front Immunol; 2019; 10():6. PubMed ID: 30761122
    [No Abstract]   [Full Text] [Related]  

  • 29. Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy.
    Emran AA; Chatterjee A; Rodger EJ; Tiffen JC; Gallagher SJ; Eccles MR; Hersey P
    Trends Immunol; 2019 Apr; 40(4):328-344. PubMed ID: 30853334
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinicopathological, immune and molecular correlates of
    Lingohr P; Dohmen J; Semaan A; Branchi V; Dietrich J; Bootz F; Kalff JC; Matthaei H; Dietrich D
    Epigenomics; 2019 May; 11(6):639-653. PubMed ID: 30821175
    [No Abstract]   [Full Text] [Related]  

  • 31. Prognostic value of JAK3 promoter methylation and mRNA expression in clear cell renal cell carcinoma.
    Long Q; Huang C; Huang J; Meng Q; Cheng Y; Li Y; He L; Chen M; Zhang C; Wang X; Zhu W; Peng J; Shi D; Zheng F; Dong P; Deng W
    J Adv Res; 2022 Sep; 40():153-166. PubMed ID: 36100323
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Can CpG methylation serve as surrogate markers for immune infiltration in cancer?
    Bacolod MD; Barany F; Fisher PB
    Adv Cancer Res; 2019; 143():351-384. PubMed ID: 31202362
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment.
    Vilgelm AE; Johnson CA; Prasad N; Yang J; Chen SC; Ayers GD; Pawlikowski JS; Raman D; Sosman JA; Kelley M; Ecsedy JA; Shyr Y; Levy SE; Richmond A
    J Natl Cancer Inst; 2016 Jun; 108(6):djv406. PubMed ID: 26719346
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Repurposing Azacitidine and Carboplatin to Prime Immune Checkpoint Blockade-resistant Melanoma for Anti-PD-L1 Rechallenge.
    van der Westhuizen A; Lyle M; Graves MC; Zhu X; Wong JWH; Cornall K; Ren S; Pugliese L; Levy R; Majid A; Vilain RE; Bowden NA
    Cancer Res Commun; 2022 Aug; 2(8):814-826. PubMed ID: 36923309
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PD-L1 methylation regulates PD-L1 expression and is associated with melanoma survival.
    Micevic G; Thakral D; McGeary M; Bosenberg MW
    Pigment Cell Melanoma Res; 2019 May; 32(3):435-440. PubMed ID: 30343532
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
    Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA
    Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174
    [No Abstract]   [Full Text] [Related]  

  • 38. Genome-wide DNA methylation profile analysis identifies an individualized predictive signature for melanoma immune response.
    Yan J; Wu X; Zhu Y; Cang S
    J Cancer Res Clin Oncol; 2023 Jan; 149(1):343-356. PubMed ID: 36595044
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of m
    Zhu M; Cui Y; Mo Q; Zhang J; Zhao T; Xu Y; Wu Z; Sun D; Zhang X; Li Y; You Q
    Front Immunol; 2021; 12():782551. PubMed ID: 34975871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical significance of the TNF-α receptors, TNFRSF2 and TNFRSF9, on cell migration molecules Fascin-1 and Versican in acute leukemia.
    El Kramani N; Elsherbiny NM; El-Gayar AM; Ebrahim MA; Al-Gayyar MMH
    Cytokine; 2018 Nov; 111():523-529. PubMed ID: 29861382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.